Claims
- 1. A method of recovering a cellular function in a cell following injury, comprising the step of:
contacting said cell with collagen IV or a natural or mutated fragment thereof.
- 2. The method of claim 1, wherein said cell comprises a renal epithelial cell.
- 3. The method of claim 1, wherein said cellular function is selected from the group consisting of Na+/K+-ATPase activity, active Na+ transport, basal oxygen consumption, and localization of collagen-binding integrins to the basal membrane.
- 4. The method of claim 1, wherein said collagen IV or said natural or mutated fragment thereof is at a concentration of from about 0.01 mM to about 100 mM.
- 5. The method of claim 1, wherein said injury is selected from the group consisting of ischemic injury, drug-induced injury and a toxicant-induced injury.
- 6. The method of claim 5, wherein said injury is selected from the group consisting of drug-induced intestine injury, toxicant-induced intestinal injury, ischemic reperfusion injury of the intestine, ischemic bowel disease, drug-induced liver injury, toxicant-induced liver injury, ischemic reperfusion injury of the liver, acute liver failure, drug-induced lung injury, toxicant-induced lung injury, ischemic reperfusion injury of the lung, acute lung failure, drug-induced heart injury, toxicant-induced heart injury, ischemic reperfusion injury of the heart, acute heart failure, drug-induced brain injury, toxicant-induced brain injury, ischemic reperfusion injury of the brain, stroke, drug-induced kidney injury, toxicant-induced kidney injury, ischemic reperfusion injury of the kidney, acute renal failure, drug-induced eye injury, toxicant-induced eye injury, ischemic reperfusion injury of the eye, chronic liver failure, chronic renal failure and vascular injury.
- 7. A pharmaceutical composition, comprising a therapeutically effective amount of collagen IV or a natural or mutated fragment thereof and a pharmaceutically acceptable carrier.
- 8. A method of recovering cellular functions following injury in an individual in need of such treatment, comprising the step of:
administering a therapeutically effective amount of the pharmaceutical composition of claim 7 to said individual.
- 9. The method of claim 8, wherein said cellular function is selected from the group consisting of Na+/K+-ATPase activity, active Na+ transport, basal oxygen consumption, and localization of collagen-binding integrins to the basal membrane.
- 10. The method of claim 8, wherein said collagen IV or said natural or mutated fragment thereof is at a concentration of from about 0.01 mg/kg to about 100 mg/kg.
- 11. The method of claim 8, wherein said injury is selected from the group consisting of ischemic injury, drug-induced injury and a toxicant-induced injury.
- 12. The method of claim 11, wherein said injury is selected from the group consisting of drug-induced intestine injury, toxicant-induced intestinal injury, ischemic reperfusion injury of the intestine, ischemic bowel disease, drug-induced liver injury, toxicant-induced liver injury, ischemic/reperfusion injury of the liver, acute liver failure, drug-induced lung injury, toxicant-induced lung injury, ischemic reperfusion injury of the lung, acute lung failure, drug-induced heart injury, toxicant-induced heart injury, ischemic/reperfusion injury of the heart, acute heart failure, drug-induced brain injury, toxicant-induced brain injury, ischemic reperfusion injury of the brain, stroke, drug-induced kidney injury, toxicant-induced kidney injury, ischemic reperfusion injury of the kidney, acute renal failure, drug-induced eye injury, toxicant-induced eye injury, ischemic reperfusion injury of the eye, chronic liver failure, chronic renal failure and vascular injury.
- 13. A method of recovering a cellular function in a cell following injury, comprising the step of:
stimulating the collagen IV receptor in said cell.
- 14. The method of claim 13, wherein said injury is selected from the group consisting of ischemic injury, drug-induced injury and a toxicant-induced injury.
- 15. The method of claim 14, wherein said injury is selected from the group consisting of drug-induced intestine injury, toxicant-induced intestinal injury, ischemic reperfusion injury of the intestine, ischemic bowel disease, drug-induced liver injury, toxicant-induced liver injury, ischemic/reperfusion injury of the liver, acute liver failure, drug-induced lung injury, toxicant-induced lung injury, ischemic reperfusion injury of the lung, acute lung failure, drug-induced heart injury, toxicant-induced heart injury, ischemic/reperfusion injury of the heart, acute heart failure, drug-induced brain injury, toxicant-induced brain injury, ischemic reperfusion injury of the brain, stroke, drug-induced kidney injury, toxicant-induced kidney injury, ischemic reperfusion injury of the kidney, acute renal failure, drug-induced eye injury, toxicant-induced eye injury, ischemic reperfusion injury of the eye, chronic liver failure, chronic renal failure and vascular injury.
- 16. The method of claim 13, wherein said collagen IV receptor is stimulated using a collagen IV antibody, a collagen IV antibody fragment or a collagen IV receptormimetic.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This non-provisional patent application claims benefit of provisional patent application No. 60/366,002, filed Mar. 20, 2002, now abandoned.
FEDERAL FUNDING LEGEND
[0002] This invention was produced in part using funds obtained through a grant from the National Institute of Environmental Health Sciences grant NIH ES-O4410. Consequently, the federal government has certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60366002 |
Mar 2002 |
US |